Emricasan

Histogen Reports First Quarter 2023 Results and Provides Business Update

Retrieved on: 
Thursday, May 11, 2023

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today reported financial results for the first quarter ended March 31, 2023, and provided an update on its pipeline and other corporate developments.

Key Points: 
  • Exclusive Intellectual Property License Agreement with Johns Hopkins – In April 2023, we signed an exclusive license agreement with Johns Hopkins University.
  • Steven J. Mento Ph.D. appointed President and CEO – In March 2023, Dr. Mento was appointed President and CEO.
  • First Quarter 2023 Financial Highlights: Three Months Ended March 31, 2023 and 2022
    Revenues for the three months ended March 31, 2023 and 2022, we recognized license revenue of $5 thousand and $3.8 million, respectively.
  • Research and development expenses for the three months ended March 31, 2023 and 2022 were $1.0 million and $1.9 million, respectively.

FUJIFILM Wako Chemicals U.S.A. Commercializes CEPT Cocktail for Research-Use iPSC Applications

Retrieved on: 
Thursday, April 20, 2023

CEPT Cocktail is intended for commercial research-use of iPSC applications including disease modeling, organoid generation, drug discovery, toxicology, and pharmacological studies.

Key Points: 
  • CEPT Cocktail is intended for commercial research-use of iPSC applications including disease modeling, organoid generation, drug discovery, toxicology, and pharmacological studies.
  • Compared to other commercially available reagents, FUJIFILM Wako Chemicals U.S.A., Corporation’s CEPT Cocktail consists of a mixture of all the components, providing comprehensive cell protection and viability.
  • Under a license granted from the National Center for Advancing Translational Sciences (NCATS) and NIH, Fujifilm commercializes CEPT cocktail as a research-use-only, ready-to-use DMSO solution.
  • “As part of a robust offering of iPSC technologies and cell culture media solutions, FUJIFILM Wako Chemicals U.S.A., Corporation is proud to commercialize the CEPT Cocktail with the hope of further advancing the role of iPSCs and their limitless potential in translational medicine,” said Toshihiro Hiramatsu, president, FUJIFILM Wako Chemicals, U.S.A., Corporation.

Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration

Retrieved on: 
Wednesday, January 18, 2023

Amerimmune LLC had a discovery early in 2020, showing elevated caspase molecules in peripheral blood immune cells of COVID19 patients.

Key Points: 
  • Amerimmune LLC had a discovery early in 2020, showing elevated caspase molecules in peripheral blood immune cells of COVID19 patients.
  • Caspase molecules help build immunity to pathogens, but can also have detrimental effects on the immune system.
  • The scientists at Amerimmune had the idea that a stronger and prolonged caspase activity can cause the poor outcomes seen in some patients with COVID-19.
  • Histogen Inc. filed for arbitration to terminate the Collaborative Development and Commercialization Agreement (CDCA) between Amerimmune and Histogen Inc.

Captivate Bio expands cell culture media focus and small molecule kits for stem cell research and emerging markets

Retrieved on: 
Tuesday, April 19, 2022

Captivate Bios custom media and procurement services will give researchers and industry partners additional options for sourcing high-quality cell culture reagents and defined media solutions, as well as provide bulk supply and custom media formulations.

Key Points: 
  • Captivate Bios custom media and procurement services will give researchers and industry partners additional options for sourcing high-quality cell culture reagents and defined media solutions, as well as provide bulk supply and custom media formulations.
  • Captivate Bios CET Cocktail complements its stem cell reagent portfolio with a key small molecule kit supporting the media supplement strategy known as CEPT (Chroman 1, Emricasan, Polyamine solution, and Trans-ISRIB).
  • CEPT is a newly published, optimized combination of targeted small molecules and culture additives shown to overcome cellular stressors inherent in stem cell workflows and address the key challenges in translational stem cell research.
  • Current product offering includes classical cell culture media, specialty media, animal sera including FBS, small molecules, biomatrices, human platelet lysate, and custom media manufacturing services for basic research, stem cell research, cell therapy, and emerging markets, such as cellular agriculture.

Histogen Announces Closing of $3.5 Million Private Placement

Retrieved on: 
Tuesday, December 21, 2021

H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement.

Key Points: 
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement.
  • The gross proceeds from this offering were approximately $3.5 million, before deducting placement agents fees and other offering expenses.
  • The Company intends to use the net proceeds from the private placement for working capital and general corporate purposes.
  • Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the bodys natural process to repair and maintain healthy biological function.

Histogen Announces $3.5 Million Private Placement

Retrieved on: 
Thursday, December 16, 2021

H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement.

Key Points: 
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement.
  • The closing of the private placement is expected to occur on or about December 20, 2021, subject to the satisfaction of customary closing conditions.
  • The Company intends to use the net proceeds from the private placement for working capital and general corporate purposes.
  • Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the bodys natural process to repair and maintain healthy biological function.

Histogen Reports Third Quarter 2021 Earnings and Provides Business Update

Retrieved on: 
Wednesday, November 10, 2021

SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today reported financial results for the third quarter ended September 30, 2021 and provided an update on its clinical pipeline and other corporate developments.

Key Points: 
  • We anticipate having top-line results from this study in the fourth quarter of 2022.
  • Pre-clinical proof-of-concept studies are ongoing, and we anticipate initial data in the fourth quarter of 2021.
  • Third Quarter Ended September 30, 2021 and 2020
    Product Revenues for the three months ended September 30, 2021 and 2020, we recognized product revenues of $0.6 million and $0.4 million, respectively.
  • As of March 31, 2021, all obligations of Histogen related to the additional supply of CCM to Allergan under the Allergan Agreements had been completed.

Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients

Retrieved on: 
Monday, August 16, 2021

SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO) and its partner Amerimmune, LLC today announced additional findings from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients to assess safety, tolerability, and preliminary efficacy. As previously reported, emricasan was shown to be safe and well tolerated during the 14 days of dosing and at the day 45 follow up, as compared to placebo, with no reports of serious adverse events. Patients who completed treatment with emricasan had a complete resolution of the symptoms most commonly associated in mild COVID-19, such as a cough, headache, and fatigue at day 7 and continued through day 45. The p-value was p

Key Points: 
  • SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO) and its partner Amerimmune, LLC today announced additional findings from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients to assess safety, tolerability, and preliminary efficacy.
  • Patients in the placebo arm who completed the study showed either delay or no symptom resolution for the duration of the study.
  • Second, patients that received emricasan showed normalization of several serum markers related to increased risk for blood clotting that are typically elevated in individuals with COVID-19.
  • Collectively, this data points to the role of emricasan in mild COVID19 and cell death as the core problem in COVID-19.

Histogen Reports Second Quarter 2021 Earnings and Provides Business Update

Retrieved on: 
Wednesday, August 11, 2021

SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today reported financial results for the second quarter ended June 30, 2021 and provided an update on its clinical pipeline and other corporate developments.

Key Points: 
  • Histogen is also evaluating the potential for additional pipeline opportunities targeting other soft tissues such as the tendon and ligament.
  • We anticipate having top-line results from this study in the second quarter of 2022.
  • We anticipate filing an IND for HST 004 in the second quarter of 2022.
  • Second Quarter Ended June 30, 2021 and 2020
    License and Service Revenues in the second quarter of 2021 decreased nearly 100% to $5 thousand from $0.1 million in the second quarter of 2020.

Histogen and Amerimmune Report Publication on Emricasan in COVID-19

Retrieved on: 
Wednesday, May 19, 2021

Histogen acquired certain rights to emricasan and other caspase inhibitor compounds as a part of its merger with Conatus Pharmaceuticals Inc. in 2020.

Key Points: 
  • Histogen acquired certain rights to emricasan and other caspase inhibitor compounds as a part of its merger with Conatus Pharmaceuticals Inc. in 2020.
  • To date, emricasan has been studied in over 950 patients in 19 completed clinical trials across a broad range of liver diseases.
  • Amerimmune LLC is a spinoff of Amerimmune Diagnostics LLC, which is focused on establishing a network of physician-owned immunology labs across the United States.
  • Amerimmune Diagnostics\xe2\x80\x99 clinical approach led to the development of the innovative therapeutics\xe2\x80\x99 technology upon which Amerimmune was founded.